Novartis announced the purchase of Pikavation Therapeutics, a wholly‑owned subsidiary of Synnovation Therapeutics, for a total consideration of up to $3 billion. The deal consists of a $2 billion upfront payment and up to $1 billion in milestone payments, bringing the PI3Kα inhibitor SNV4818 into Novartis’s oncology portfolio. SNV4818 is a pan‑mutant selective inhibitor that is currently in Phase 1/2 trials for breast cancer and other advanced solid tumors.
The acquisition is designed to strengthen Novartis’s position in hormone‑receptor positive, HER2‑negative breast cancer, a market in which approximately 40% of patients carry PIK3CA mutations. By adding SNV4818, Novartis gains a next‑generation PI3Kα inhibitor that selectively targets mutant forms while sparing wild‑type enzyme, potentially improving tolerability and enabling combination therapies. The asset complements Novartis’s existing PI3Kα drug, Piqray, and expands the company’s ability to offer differentiated treatment options.
SNV4818’s mutant‑selective chemistry is expected to reduce side‑effects that have limited the clinical use of earlier PI3Kα inhibitors. The drug is currently in Phase 1/2 studies, with results anticipated in 2027. Its design aims to provide durable benefit for patients with PI3Kα‑driven tumors while maintaining a safety profile that could allow broader use in combination regimens.
The PI3Kα inhibitor landscape remains competitive, with Novartis’s Piqray, Roche’s Itovebi, and AstraZeneca’s Truqap already approved or in late‑stage development. SNV4818 seeks to differentiate itself through its selective targeting of mutant PI3Kα, potentially offering a therapeutic advantage over existing agents that inhibit both mutant and wild‑type forms.
Management highlighted the strategic fit of the acquisition. Shreeram Aradhye, President of Development at Novartis, said, "While mutated PI3Kα is a well‑established driver in HR+/HER2- breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile. SNV4818 applies new mutant‑selective chemistry to more precisely target tumour biology while sparing normal cells. This approach has the potential to translate proven biology into improved tolerability and more durable benefit for patients through precision medicine." Wenqing Yao, CEO of Synnovation, added, "We believe Novartis's global capabilities and commitment to patients with cancer will accelerate the development of SNV4818 for patients with PI3Kα mutation–driven solid tumors beyond what Synnovation could achieve alone."
The deal signals Novartis’s continued focus on expanding its oncology pipeline and underscores its commitment to developing next‑generation therapies that address unmet needs in breast cancer. By acquiring a promising PI3Kα inhibitor with a potentially superior safety profile, Novartis positions itself to strengthen its competitive stance in a crowded therapeutic area and accelerate the delivery of innovative treatments to patients.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.